Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. | Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. | Helsinn Group Helsinn Group is a pharmaceutical company that focuses on therapeutic and supportive care products for cancer. | Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products. | ||
Founding Date | Founding Date 1998 | Founding Date 2008 | Founding Date 2013 | Founding Date 1976 | Founding Date 2003 |
Type | Type Subsidiary | Type Public | Type Subsidiary | Type Private | Type Subsidiary |
Tags | |||||
Locations | Locations Paris, FR HQ | Locations Cambridge, US HQ | Locations San Diego, US HQ | Locations Pazzallo, CH HQ Shanghai, CN Monaco, MC Biasca, CH Woodbridge Township, US | Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Tomsk, RU Ufa, RU |
Employees | Employees 7517% decrease | Employees 53611% increase | Employees 25024% increase | Employees 400 | Employees 1,56135% increase |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $26.8m (FY, 2023) | Revenue (est.) $30.8m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) ₽142.9b (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $2.9m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods ₽109.3b (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $23.9m (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit ₽33.6b (FY, 2023) |
Net income | Net income N/A | Net income ($352.1m) (FY, 2023) | Net income ($236.6m) (FY, 2021) | Net income N/A | Net income ₽23.3b (FY, 2023) |